C4 Therapeutics, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- C4 Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2026-06-30 was $0.00.
- C4 Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2026-03-31 was $200.00K, a 29.03% increase year-over-year.
- C4 Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $14.00K.
- C4 Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $24.00K, a 71.76% decline year-over-year.
- C4 Therapeutics, Inc. payments for repurchase of common stock for fiscal 2025 was $193.00K, a 0.52% decline from fiscal 2024.
- C4 Therapeutics, Inc. payments for repurchase of common stock for fiscal 2024 was $194.00K, a 76.36% increase from fiscal 2023.
- C4 Therapeutics, Inc. payments for repurchase of common stock for fiscal 2023 was $110.00K.
- C4 Therapeutics, Inc. payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $238.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-12 | $238.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $193.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $179.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $240.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $155.00K 10-Q · filed 2026-05-12 | $240.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $194.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $194.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $125.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $109.00K 10-Q · filed 2025-05-07 | $125.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $110.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $110.00K derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $94.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $94.00K 10-Q · filed 2024-05-08 | $94.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | |
| 2020-12-31 | -$16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $194.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2019-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $30.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |